Page last updated: 2024-12-11

hemiasterlin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hemiasterlin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5352092
CHEMBL ID185151
SCHEMBL ID57313
MeSH IDM0440841

Synonyms (17)

Synonym
nsc-695242
NSC695242 ,
hemiasterlin
CHEMBL185151
(e,4s)-4-[[(2s)-3,3-dimethyl-2-[[(2s)-3-methyl-2-(methylamino)-3-(1-methylindol-3-yl)butanoyl]amino]butanoyl]-methylamino]-2,5-dimethylhex-2-enoic acid
milnamide b
l-valinamide, n,beta,beta,1-tetramethyl-l-tryptophyl-n-((1s,2e)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl)-n,3-dimethyl-
6s0t7u2i3f ,
157207-90-4
(-)-hemiasterlin
unii-6s0t7u2i3f
SCHEMBL57313
l-valinamide, n,.beta.,.beta.,1-tetramethyl-l-tryptophyl-n-((1s,2e)-3-carboxy-1-(1-methylethyl)-2-buten-1-yl)-n,3-dimethyl-
Q27265411
(s,e)-2,5-dimethyl-4-((s)-n,3,3-trimethyl-2-((s)-3-methyl-3-(1-methyl-1h-indol-3-yl)-2-(methylamino)butanamido)butanamido)hex-2-enoic acid
HY-117371
AKOS040752003

Research Excerpts

Overview

Hemiasterlin is a natural product derived from marine sponges. It binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules.

ExcerptReferenceRelevance
"Hemiasterlin is an antimitotic marine natural product with reported sub-nanomolar potency against several cancer cell lines. "( Expeditious Total Synthesis of Hemiasterlin through a Convergent Multicomponent Strategy and Its Use in Targeted Cancer Therapeutics.
Carroll, JS; Charoenpattarapreeda, J; Spring, DR; Walsh, SJ, 2020
)
2.29
"Hemiasterlin is a natural product derived from marine sponges that, like other structurally diverse peptide-like molecules, binds to the Vinca-peptide site in tubulin, disrupts normal microtubule dynamics, and, at stoichiometric amounts, depolymerizes microtubules. "( HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo.
Andersen, RJ; Annable, T; Ayral-Kaloustian, S; Baxter, M; Beyer, C; Discafani, CM; Fojo, T; Greenberger, LM; Hardy, C; Hari, M; Hernandez, R; Khafizova, G; Loganzo, F; Musto, S; Nieman, JA; Poruchynsky, MS; Singanallore, T; Tan, X; Zask, A, 2003
)
2.02
"Hemiasterlin is a potent antimitotic peptide that interferes with microtubule dynamics at picomolar concentrations in cell culture. "( A missense mutation in Caenorhabditis elegans prohibitin 2 confers an atypical multidrug resistance.
Doundoulakis, T; Harran, PG; Roth, MG; Zubovych, I, 2006
)
1.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID354406Cytotoxicity activity against human MCF7 cells expressing p53 mutant by MTT assay2003Journal of natural products, Feb, Volume: 66, Issue:2
Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues.
AID248904Concentration required to kill human epidermoid KB-3-1 cell lines containing very low levels of P-glycoprotein after 3 days of continuous exposure2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.
AID248874Concentration required to kill human epidermoid KB85 cell lines containing moderate levels of P-glycoprotein after 3 days of continuous exposure2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.
AID248889Concentration required to kill human epidermoid KBV1 cell lines containing very high levels of P-glycoprotein after 3 days of continuous exposure2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.
AID252057Percent inhibition of bovine microtubule-assisted protein (MAP) rich tubulin polymerisation at concentration of 0.3 uM; Not applicable2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and activity of novel analogs of hemiasterlin as inhibitors of tubulin polymerization: modification of the A segment.
AID1304574Antiproliferative activity against human MCF7 cells after 20 hrs by microculture tetrazolium assay2016Journal of natural products, Mar-25, Volume: 79, Issue:3
The Halicylindramides, Farnesoid X Receptor Antagonizing Depsipeptides from a Petrosia sp. Marine Sponge Collected in Korea.
AID354405Antimitotic activity against human MCF7 cells expressing p53 mutant by MTT assay2003Journal of natural products, Feb, Volume: 66, Issue:2
Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (53.33)29.6817
2010's13 (43.33)24.3611
2020's1 (3.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.28 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]